Scientific Information. The Parties recognise the importance, when preparing and implementing measures aimed at protecting the environmental and social conditions that affect trade between the Parties, of taking account of scientific and technical information, and relevant international standards, guidelines or recommendations.
Scientific Information. The Parties recognise the importance, when preparing and implementing measures aimed at protecting health and safety at work or the environment which affect trade between the Parties, of taking into account scientific and technical information and relevant international standards, guidelines or recommendations, while acknowledging that, where there are threats of serious or irreversible damage, the lack of full scientific certainty should not be used as a reason for postponing protective measures [81].
Scientific Information. When preparing and implementing measures aimed at protecting the environment or labour conditions that could affect trade or investment between the Parties, each Party shall take account of available scientific and technical information, as well as relevant international standards, guidelines and recommendations if they exist, including the precautionary principle.
Scientific Information. During the Term, each Party will submit to the other Party for review and approval all proposed academic, scientific and medical publications and public presentations relating to Products within the Field for review in connection with preservation of patent rights and/or to determine whether any of such other Party’s Confidential Information should be modified or deleted. Written copies of such proposed publications and presentations shall be submitted to the non-publishing Party no later than [ * ] before submission for publication or presentation and the non-publishing Party shall provide its comments with respect to such publications and presentations within [ * ] of its receipt of such written copy. The publishing Party shall delay the submission for publication or presentation for a period of up to [ * ] in the event the non-publishing Party can demonstrate reasonable need for such delay, including without limitation, the preparation and filing of patent applications. By mutual agreement, this period may be further extended. In addition, upon the non-publishing Party’s request, the publishing Party shall delete from the proposed submission any Confidential Information of the non-publishing Party; provided, however, that with respect to a [ * ] or [ * ] by the [ * ] regarding [ * ] data or information, the [ * ] shall [ * ] or [ * ] to the [ * ] or [ * ] of such [ * ]. Trubion and Facet will each comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publications relating to Products within the Field. Notwithstanding the rest of this Section 11.2, the Opt-Out Party may not publish any academic, scientific or medical publications or make any public presentations regarding the Royalty Product without the prior written consent of the Non-Opt-Out Party.
Scientific Information. In conformity with Article VIII.B of the Statute, Poland shall make available to the IAEA without charge all scientific information developed as a result of the assistance provided by the IAEA for the Project.
Scientific Information. 1) Prior to or, if not previously delivered, upon execution of this Agreement, F-DE shall deliver to SALMEDIX any and all Scientific Information generated or compiled by or on behalf of F-DE including, without limitation, communications to and from regulatory agencies (including, without limitation, registrational packages submitted by or on behalf of F-DE to such agencies), marketing strategies, manufacturing know-how, the Drug Master File and such other information and data necessary or useful for SALMEDIX to develop the Compound and Product and to manufacture, have manufactured, market, sell, import, distribute and/or promote the Product and for SALMEDIX to register the same throughout the Territory and qualify back-up manufacturer(s) for SALMEDIX’s marketing and sale of the Product (collectively “Data”). For the avoidance of doubt, Scientific Information and Data shall also include any such information and data generated by another entity which has gained rights to develop, market or commercialize the Product throughout the world from F-DE or any of its Affiliates and which would be necessary or useful for SALMEDIX to develop the Compound and Product and to manufacture, have manufactured, market, sell, import, distribute and/or promote the Product, and F-DE shall ensure that SALMEDIX has access to such Scientific Information and Data pursuant to Paragraph 2 below. For the purpose of this Agreement, any and all Scientific Information and Data disclosed by F-DE to SALMEDIX before execution of this Agreement shall be deemed to have been disclosed hereunder.
Scientific Information. In conformity with Article VIII.B of the Statute, Portugal shall make available to the IAEA without charge all scientific information developed as a result of the assistance provided by the IAEA for the Project.
Scientific Information. In conformity with Article VIII.B of the Statute, Nigeria shall make available to the IAEA without charge all scientific information developed as a result of the assistance provided by the IAEA for the project.
Scientific Information. In conformity with Article VIII.B of the Statute, Chile shall make available to the Agency without charge all scientific information developed as a result of the assistance provided by the Agency for the project.
Scientific Information. Within 20 Business Days after the Effective Date, subject to Chimerix’s receipt of the Upfront Payment, Chimerix shall disclose to SymBio all existing data and information generated in any preclinical or clinical study of Compound or Product in the Field conducted by or on behalf of Chimerix, including a copy of the final study report from each such study, and provide to SymBio copies of all Regulatory Documentation for Compound and Product in the Field in Chimerix’s possession. Subject to the terms and conditions of this Agreement, Chimerix grants SymBio the right to access and reference all Product Filings for Product in the Territory that are held by Chimerix [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. as of the Effective Date or during the Term, solely for the purpose of obtaining and maintaining regulatory approvals for Product in the Field in the Territory; and SymBio grants Chimerix the right to access and reference all Product Filings for Product in the Territory that are held by SymBio or any of its Affiliates or Sublicensees during the Term, solely for the purpose of obtaining and maintaining regulatory approvals for Product outside the Field in the Territory. Any translation costs associated with any access and reference of future regulatory filings and correspondences with Regulatory Authorities under this Agreement shall be borne by the Party seeking the right to access and reference the applicable filing. Each Party shall, promptly upon request of the other Party, file with applicable Regulatory Authorities such letters of authorization, access or cross-reference as may be necessary to accomplish the intent of this Section 2.3(d).
